NATICK, Mass., May 9 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Paris Course on Revascularization (EuroPCR), which runs from May 16 to 19 in Paris.
"The data we will present at EuroPCR builds on the continued strength and leadership of the TAXUS brand of coronary stent systems," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "We expect this data will offer further evidence of the performance and durability of our current drug-eluting stent platform, as well as the deliverability and efficacy of our second-generation product, the TAXUS Liberte paclitaxel-eluting coronary stent system."
Tuesday, May 16 (all times are Paris time)
* Symposium on drug-eluting stents. At 1:30 p.m., the Company will host a
symposium entitled "The Great Debate on drug-eluting stents," chaired
by Jean Marco, M.D., in Room 1 of the Palais des Congres, 2 Place de la
Porte Maillot, Paris. The symposium will focus on key issues related
to drug-eluting stent (DES) usage in daily practice and will review the
options and decision criteria for the usage of the TAXUS®
paclitaxel-eluting coronary stent systems versus other platforms through
evidence-based medicine.
* Peripheral interventions trial data. At 1:43 p.m., nine-month results
from the RENAISSANCE clinical trial will be presented by Krishna
Rocha-Singh, M.D., F.A.C.C., the study's principal investigator, at a
late-breaking trials session in Room 2. RENAISSANCE is a prospective,
multi-center trial designed to confirm the safety and efficacy of the
Express® SD stent for renal artery stenting. At 1:45 p.m., one-year
results from the MELODIE clinical trial will be presented by Luc
Stockx, M.D., at a late-breaking trials session in Room 2. MELODIE is
a prospective, multi-center trial designed to confirm the safety and
efficacy of the Express™ Vascular LD stent for the treatment of
iliac artery lesions. The Company will issue a press release on the
MELODIE results at this time.
* ATLAS nine-month data. At 5:20 p.m., nine-month results from the ATLAS
clinical trial will be presented by Mark Turco M.D., F.A.C.C., the
study's co-principal investigator, at a late-breaking trials session in
Room 1. The ATLAS clinical trial is a global, multi-center, pivotal
study designed to support U.S. Food and Drug Administration approval of
TAXUS Liberte™, the Company's second generation, paclitaxel-eluting
stent system. ATLAS studies the TAXUS Liberte stent system, compared
to a case-matched control group of TAXUS Express2™ patients from
TAXUS IV and TAXUS V de novo studies. ATLAS is the first global trial
of a second-generation DES. The Company will also issue a press
release at this time.
* TAXUS VI long-term data. At 5:52 p.m., the Company will release
three-year results from its TAXUS VI clinical trial, which evaluates the
safety and efficacy of a moderate-release formulation of its TAXUS
Express2 paclitaxel-eluting stent in high-risk patients, including long
lesions, small vessels and diabetics. (The Company's current
commercialized product uses a slow-release formulation.) The results
will be presented by Keith Dawkins, M.D., the study's co-principal
investigator, at a late-breaking trials session in Room 1. The Company
will also issue a press release at this time.
* STENT Registry nine-month update. At 6:02 p.m., nine-month results from
the Strategic Transcatheter Evaluation of New Therapies (STENT)
registry will be presented by Thomas Stuckey, M.D., at a late-breaking
trials session in Room 1. This large, independent, prospective,
multi-center registry evaluates the comparative late clinical outcomes
of paclitaxel- and sirolimus-eluting coronary stents among "real-world"
cases and clinical situations, including diabetics and other high-risk
patients. With a planned enrollment of more than 8,000 patients, the
STENT registry is the largest study of its kind in the United States.
Boston Scientific will present its latest innovations at booth #F14, including the iLab Ultrasound Imaging System -- a completely functional IVUS system designed to be installed into a cath lab.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, litigation, the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange Commission.
CONTACT: Milan Kofol 508-650-8569 (Office) Investor Relations Boston Scientific Corporation Charles Rudnick 508-650-8660 (Office) 617-935-1789 (Mobile) Media Relations Boston Scientific Corporation
SOURCE: Boston Scientific Corporation
CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or Charles
Rudnick, Media Relations, +1-508-650-8660, or +1-617-935-1789 (Mobile), both
of Boston Scientific Corporation
Web site: http://www.bostonscientific.com/